News

Doravirine/islatravir (Idvynso), is a non-INSTI, tenofovir-free alternative for virologically suppressed adults, with efficacy, safety, and potential benefits for aging populations managing complex treatment needs. Amy Colson, MD, MPH, offers some insights about the phase 3 trial and how clinicians may want to consider its use for patients.

Jonathan Batchelder, PhD, provides insights around his research that showed that Staphylococcus aureus can survive fluoroquinolone treatment under nutrient-limited conditions even without key DNA repair proteins, pointing to alternative survival pathways and implications for future therapies.

Emerging evidence suggests that confirming hepatitis C cure at 4 weeks post-treatment could improve patient engagement and reduce barriers to care without compromising accuracy. Meghan D. Morris, PhD, MPH, offers insights around her study on this subject.

The agency’s acting director took the unusual step of withholding the publication of the study findings in the Morbidity and Mortality Weekly Report, which showed the vaccine was protective against hospitalization and emergency department visits.

Results from a large population-based study found that receiving influenza and pertussis vaccines on the same day during pregnancy does not increase the risk of adverse maternal, birth, or neonatal outcomes compared with pertussis vaccination alone.

The federal agency has given the nod to doravirine/islatravir (Idvynso), a once-daily, 2-drug HIV treatment that demonstrated noninferior efficacy to standard 3-drug regimens in phase 3 trials, expanding options for adults with virological suppression.

Our short survey underscores the critical role of audience feedback in shaping more relevant, impactful infectious disease coverage.

In the third part of our conversation with the Peggy Lillis Foundation’s CEO Christian Lillis, he says insurance restrictions are forcing people with C diff to endure inferior treatments and repeated infections raising both human suffering and long-term healthcare costs.

A major international study reveals that World Health Organization-recommended first-line antibiotics are effective in only one in four neonatal sepsis infections in low- and middle-income countries, underscoring the growing threat of antimicrobial resistance.

New research shows that antiretroviral therapy can reduce HIV-related accelerated biological aging by nearly 4 years, highlighting the critical importance of early and sustained treatment.

This week, read about AI and antibiotic development, an innovative hepatitis C program to get postpartum mothers tested and treated sooner, on World Liver Day a nurse talks about her personal story and how she advocate for better education around this vital organ, and more.

A large real-world study from the UK Health Security Agency presented at ESCMID Global 2026 finds that maternal RSV vaccination given at least two weeks before birth cuts infant hospitalizations by more than 80%.

The latest CDC numbers show only a 0.40% increase of measles cases from week-to-week. This continues a downward trend in the percentage of cases from last week where there was only a 2.57% increase.

In honor of World Liver Day 2026, a nurse shares the heartbreaking story of her son’s fatal liver disease and her lifelong mission to educate the public about the vital, often overlooked role of liver health.

Lily Li, MD, PhD, MBA, discusses factors for increasing incidence rates including low awareness, asymptomatic spread, and gaps in testing and care access, and strategies to increase early. She also provides a brief overview for some of the testing options for the infectious disease.

In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.

Madeline McCrary, MD, explains her institution’s program as a novel way to get new mothers diagnosed and given their full-course of treatment when they are still in the hospital.

Study ascertains vaccination status of children hospitalized for Bordetella pertussis infections and assesses diagnostic value of testing modalities.

In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.

A nurse’s decades-long advocacy highlights how personal loss and gaps in public education have shaped ongoing challenges in hepatitis B vaccination and liver disease awareness.

A new study shows that strain-level surveillance of Staphylococcus aureus in NICUs can identify hidden transmission pathways and enable targeted interventions to reduce serious infections in vulnerable newborns.

Akhila Kosaraju, MD, provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm.

Study examines how clinicians consider rapid pneumonia panel test results in prescribing antibiotics in the ICU.

The latest CDC numbers show a 2.57% increase of measles cases from week-to-week. This is a significant decrease in the percentage of cases from last week where there was a 6.1% increase.

Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.

A large cluster-randomized trial in Singapore found that releasing sterile male Wolbachia-infected mosquitoes greatly reduced dengue infections by suppressing local mosquito populations.

The inaugural MAD-ID and SIDP 2026 meeting aims to provide new infectious diseases education offerings, dynamic speakers, and strong networking opportunities for younger clinicians. SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, offers some insights around the upcoming event.

Investigators identified behavioral determinants of being tested for pathogen exposure, in interviewing a focus group presented with a hypothetical avian influenza outbreak.